health
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO defended the company's decision to sue rival Eli Lilly over its weight-loss drug advertising.
TL;DR
- Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly concerning weight-loss drug advertising.
- Doustdar argued that Eli Lilly's advertising for its GLP-1 drugs is misleading because it relies on older, lower-dose versions of Novo Nordisk's Wegovy, not the newer 7.2 mg version.
- Eli Lilly stated that their advertising is truthful and that comparisons to their Zepbound are not supported by head-to-head clinical trials.
- The lawsuit is part of intensified competition between the two companies in the growing GLP-1 market.
- Novo Nordisk recently launched a Wegovy pill, which they claim is the best product launch in pharmaceutical history, while Eli Lilly's weight-loss pill, Foundayo, missed expectations.
- Novo Nordisk shares have fallen since the lawsuit was filed, while Eli Lilly shares have climbed.